Laura Tufano

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Comparative Study of Sporadic and Immune Checkpoint Inhibitor-Related Forms of Myasthenia Gravis-Myositis Overlap Syndrome.

Comparative Study of Sporadic and Immune Checkpoint Inhibitor-Related Forms of Myasthenia Gravis-Myositis Overlap Syndrome.

Journal: Neurology

Published: May 26, 2026

Immune-mediated necrotizing myopathies: clinico-serological features and treatment outcomes of a large Italian cohort of patients.

Immune-mediated necrotizing myopathies: clinico-serological features and treatment outcomes of a large Italian cohort of patients.

Journal: Journal of neurology

Published: May 04, 2026

Test-Retest Reliability of Remote Assessments in Patients With Myotonic Dystrophy Type 1.

Test-Retest Reliability of Remote Assessments in Patients With Myotonic Dystrophy Type 1.

Journal: Neurology

Published: February 25, 2026

Sporadic late-onset nemaline myopathy (SLONM): Data from a case series and literature review of 144 patients.

Sporadic late-onset nemaline myopathy (SLONM): Data from a case series and literature review of 144 patients.

Journal: Autoimmunity reviews

Published: August 06, 2025

Response to letter to the editor: "Emergent role of complement inhibitors in myasthenic crisis" (CNN-D-25-2224).

Response to letter to the editor: "Emergent role of complement inhibitors in myasthenic crisis" (CNN-D-25-2224).

Journal: Clinical neurology and neurosurgery

Published: July 17, 2025

Response to comment on: "Emergent role of complement inhibitors in myasthenic crisis - Complement for crisis, FcRn for continuity (CNN-D-25-2177)".

Response to comment on: "Emergent role of complement inhibitors in myasthenic crisis - Complement for crisis, FcRn for continuity (CNN-D-25-2177)".

Journal: Clinical neurology and neurosurgery

Published: July 17, 2025

Emergent role of complement inhibitors in myasthenic crisis: Understanding why, when and how.

Emergent role of complement inhibitors in myasthenic crisis: Understanding why, when and how.

Journal: Clinical neurology and neurosurgery

Published: March 28, 2025

Ravulizumab for generalized Myasthenia Gravis: a multicenter real-life experience.

Ravulizumab for generalized Myasthenia Gravis: a multicenter real-life experience.

Journal: Journal of neurology

Published: March 12, 2025

Correction: Muscle MRI as a biomarker of disease activity and progression in myotonic dystrophy type 1: a longitudinal study.

Correction: Muscle MRI as a biomarker of disease activity and progression in myotonic dystrophy type 1: a longitudinal study.

Journal: Journal of neurology

Published: February 01, 2025

Pharmacogenetic pilot study of CYP2D6 and CYP1A2 genes in Italian patients with non-dystrophic myotonia and myotonic dystrophy treated with mexiletine.

Pharmacogenetic pilot study of CYP2D6 and CYP1A2 genes in Italian patients with non-dystrophic myotonia and myotonic dystrophy treated with mexiletine.

Journal: Gene

Published: October 28, 2024

Integrating D4Z4 methylation analysis into clinical practice: improvement of FSHD molecular diagnosis through distinct thresholds for 4qA/4qA and 4qA/4qB patients.

Integrating D4Z4 methylation analysis into clinical practice: improvement of FSHD molecular diagnosis through distinct thresholds for 4qA/4qA and 4qA/4qB patients.

Journal: Clinical epigenetics

Published: June 18, 2024

Management of overlapping immune-related myocarditis, myositis, and myasthenia in a young patient with advanced NSCLC: a case report.

Management of overlapping immune-related myocarditis, myositis, and myasthenia in a young patient with advanced NSCLC: a case report.

Journal: Frontiers in oncology

Published: May 13, 2024

Showing 1-12 of 23

Last Updated: 09/26/2026